

## Company Fact Sheet

CSL Behring, a member of the CSL Group of companies, is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies to treat people in more than 60 countries with serious and life-threatening medical conditions.

We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.

Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop and dependably deliver innovations that patients and providers want.

We have more than 1,700 dedicated scientists who focus on solving patients' unmet needs. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (AXS:CSL; USOTC:CSLLY), is headquartered in Melbourne, Australia.

### THERAPEUTIC AREAS

**Immunology:** For treatment of immunodeficiency and autoimmune diseases such as primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura and Guillain-Barré syndrome, and to prevent hemolytic disease of the newborn and cytomegalovirus infection in patients following solid organ transplant.

**Hematology:** For treatment of coagulation or bleeding disorders, including hemophilia and von Willebrand disease.

**Specialty:** For treatment of hereditary angioedema and for warfarin reversal, Alpha-1 antitrypsin deficiency (hereditary emphysema), wound healing, shock, burns, sepsis and during surgery.

### EMPLOYEES

20,000+ employees worldwide

### OPERATIONAL HEADQUARTERS

King of Prussia, Pennsylvania, USA

### PLASMA COLLECTION

More than 200 collection centers in the USA and Europe


### MANUFACTURING

Bern, Switzerland; Marburg, Germany; Broadmeadows, Australia; Kankakee, Illinois, USA; Wuhan, China

### 2017-2018 | CSL Behring Sales - \$6.7 Billion

#### Therapeutic Group

Therapy	Sales \$m	% Change
Immunoglobulins	3,145	11%
Hemophilia	1,113	5%
Albumin	921	7%
Specialty	1,490	24%
Other	9	
<b>Total</b>	<b>6,678</b>	<b>11%</b>



For more information, visit [CSLBehring.com](http://CSLBehring.com).

For inspiring stories about the promise of biotechnology, visit Vita at [CSLBehring.com/Vita](http://CSLBehring.com/Vita).

### FOLLOW US ON

[@CSLBering](https://twitter.com/CSLBering)  
[linkedin.com/company/csl-behring](https://linkedin.com/company/csl-behring)